Your browser is no longer supported. Please, upgrade your browser.
Settings
FLXN Flexion Therapeutics, Inc. daily Stock Chart
FLXN [NASD]
Flexion Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.46 Insider Own0.60% Shs Outstand37.41M Perf Week-6.09%
Market Cap975.28M Forward P/E- EPS next Y-3.01 Insider Trans0.00% Shs Float37.09M Perf Month-1.84%
Income-155.20M PEG- EPS next Q-1.22 Inst Own- Short Float27.91% Perf Quarter-0.15%
Sales2.50M P/S390.11 EPS this Y-46.50% Inst Trans2.78% Short Ratio14.85 Perf Half Y10.98%
Book/sh5.92 P/B4.40 EPS next Y41.10% ROA-39.70% Target Price38.60 Perf Year39.11%
Cash/sh9.93 P/C2.62 EPS next 5Y- ROE-72.20% 52W Range16.51 - 32.25 Perf YTD4.11%
Dividend- P/FCF- EPS past 5Y-32.60% ROI-30.90% 52W High-19.16% Beta0.80
Dividend %- Quick Ratio15.50 Sales past 5Y- Gross Margin-6.00% 52W Low57.90% ATR1.10
Employees251 Current Ratio15.60 Sales Q/Q- Oper. Margin- RSI (14)53.11 Volatility3.52% 4.31%
OptionableYes Debt/Eq0.72 EPS Q/Q-47.10% Profit Margin- Rel Volume0.45 Prev Close25.91
ShortableYes LT Debt/Eq0.67 EarningsMay 08 AMC Payout- Avg Volume697.27K Price26.07
Recom1.70 SMA20-0.04% SMA504.38% SMA2006.24% Volume315,062 Change0.62%
Oct-09-17Reiterated Needham Buy $36 → $42
Aug-24-17Initiated Northland Capital Outperform
Dec-22-16Initiated Raymond James Strong Buy
Sep-06-16Resumed Lake Street Buy $38
Jul-21-16Initiated Lake Street Buy $38
May-03-16Resumed Wells Fargo Outperform
Nov-04-15Initiated Cantor Fitzgerald Buy
Sep-09-15Reiterated Needham Buy $31 → $28
May-14-15Initiated Northland Capital Outperform $40
Mar-31-15Initiated MLV & Co Buy $38
Aug-14-14Initiated Summer Street Research Buy $25
Mar-10-14Initiated Needham Buy $26
May-10-18 03:46AM  Edited Transcript of FLXN earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 05:37PM  Flexion Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
May-07-18 07:30AM  Flexion Therapeutics Names David Arkowitz as Chief Financial Officer GlobeNewswire
May-04-18 07:30AM  Flexion Therapeutics Announces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS GlobeNewswire
May-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-30-18 04:30PM  Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018 GlobeNewswire
Apr-29-18 09:00AM  Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress GlobeNewswire
Apr-26-18 07:30AM  Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at Osteoarthritis Research Society International World Congress GlobeNewswire +5.52%
Apr-24-18 04:30PM  Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018 GlobeNewswire
Apr-18-18 04:20PM  Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery GlobeNewswire
Apr-06-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:38AM  Why Flexion Therapeutics (FLXN) Could Be Positioned for a Slump Zacks
Apr-05-18 07:55AM  Detailed Research: Economic Perspectives on The Habit Restaurants, MUELLER WATER PRODUCTS, The Carlyle Group, Flexion Therapeutics, Hexcel, and Adesto Technologies What Drives Growth in Today's Competitive Landscape GlobeNewswire -5.25%
Mar-19-18 09:00AM  Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference GlobeNewswire
Mar-09-18 06:10PM  Edited Transcript of FLXN earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
04:15PM  Why A Key Drug Launch Wasn't Enough To Help This Biotech Stock Investor's Business Daily
Mar-08-18 05:05PM  Flexion Therapeutics reports 4Q loss Associated Press
04:01PM  Flexion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
01:00PM  Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-18 09:00AM  Flexion Therapeutics to Present at the Cowen 38th Annual Health Care Conference GlobeNewswire
Mar-06-18 07:30AM  Flexion Therapeutics Presents Clinical Data at AAOS 2018 Annual Meeting and the American Pain Society Annual Scientific Meeting GlobeNewswire
Mar-02-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-28-18 09:00AM  Flexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors Conference GlobeNewswire
Feb-26-18 04:30PM  Flexion Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 8, 2018 GlobeNewswire
Feb-14-18 04:30PM  Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
Feb-08-18 07:55AM  New Research: Key Drivers of Growth for Radian Group, Flexion Therapeutics, Andeavor, Haverty Furniture Companies, Ares Capital, and Sempra Energy Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-02-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-08-18 07:30AM  Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Dec-29-17 09:00PM  3 Biotechs Launching Their First Commercial Drugs in 2018 Motley Fool
03:00AM  Flexion Therapeutics Getting Closer To Key Technical Measure Investor's Business Daily
Dec-18-17 04:05PM  Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in Osteoarthritis of the Shoulder and Hip GlobeNewswire
Dec-13-17 04:05PM  Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee GlobeNewswire
Dec-11-17 04:05PM  Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer GlobeNewswire
Dec-10-17 07:16PM  2018 Is a Critical Year for These 3 Small Commercial-Stage Biotech Stocks Motley Fool
Dec-07-17 04:35PM  Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the Knee GlobeNewswire
Dec-06-17 04:30PM  Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-04-17 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-30-17 05:01PM  Flexion's (FLXN) Zilretta Therapy to Fast Capture OA Market Zacks
Nov-29-17 03:00AM  Stocks To Watch: Flexion Therapeutics Sees RS Rating Jump To 83 Investor's Business Daily
Nov-28-17 04:05PM  Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference GlobeNewswire
11:58AM  Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte Forbes
07:14AM  This Small-Cap Biotech Stock Is Onto Something Big Motley Fool
Nov-27-17 08:00AM  Today's Research Reports on Stocks to Watch: Flexion Therapeutics and Teva Pharmaceutical ACCESSWIRE -7.03%
Nov-20-17 07:30AM  Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Nov-17-17 09:00AM  Flexion Therapeutics Named Top Place to Work for 2017 by The Boston Globe GlobeNewswire
Nov-08-17 08:41PM  Edited Transcript of FLXN earnings conference call or presentation 6-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-17 01:23PM  Is There Now An Opportunity In Flexion Therapeutics Inc (FLXN)? Simply Wall St.
Nov-06-17 05:07PM  Flexion Therapeutics reports 3Q loss Associated Press
04:05PM  Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
03:00AM  Flexion Therapeutics Getting Closer To Key Technical Measure Investor's Business Daily
Nov-02-17 04:05PM  Flexion Therapeutics Highlights Two Clinical Data Presentations at the 2017 American College of Rheumatology Annual Meeting GlobeNewswire
Oct-30-17 04:05PM  Flexion Therapeutics to Report Third-Quarter 2017 Financial Results on November 6, 2017 GlobeNewswire
Oct-25-17 01:18PM  Stocks on My Radar on This Selling TheStreet.com -5.68%
Oct-17-17 01:55PM  Applied Optoelectronics, Helios And Matheson Among The Top Stocks With Short Sellers Benzinga
Oct-15-17 05:00PM  Flexion's Latest FDA Approval Reignites Takeover Chatter TheStreet.com
Oct-13-17 01:15AM  A New FDA Approval Sends Small Cap Flexion Soaring Motley Fool
Oct-11-17 05:55PM  Flexion Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
09:23AM  Flexion Shares Lower After Proposed Stock Offering -- Biotech Movers TheStreet.com
Oct-10-17 04:05PM  Flexion Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Oct-09-17 04:19PM  Flexion CEO: Absolutely thinking about exploring additional uses for new non-opioid drug CNBC -5.65%
02:33PM  Flexion CEO on non-opioid knee pain treatment CNBC Videos
10:15AM  Flexion's Zilretta Gets FDA Approval for Knee Pain, Stock Up Zacks
09:21AM  Flexion Shares Continue Rise After FDA Approval -- Biotech Movers TheStreet.com
09:00AM  Flexion Can Double Now That FDA Has Approved Zilretta Forbes
08:51AM  Flexion Therapeutics (FLXN) in Focus: Stock Moves 10.4% Higher Zacks
07:00AM  Flexion Therapeutics to Hold Conference Call at 8:00 a.m. ET to Discuss Recent FDA Approval of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) PR Newswire
03:00AM  Flexion Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily
Oct-07-17 10:20AM  Flexion shares surge on FDA approval for its non-opioid knee pain medication MarketWatch
Oct-06-17 04:30PM  Flexion's knee pain drug gets FDA nod, shares hit life high Reuters +10.36%
04:26PM  This Biotech Could Reap North Of $1 Billion For Painkiller Investor's Business Daily
04:12PM  Edited Transcript of FLXN earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents
03:45PM  Flexion Secures FDA Nod for Osteoarthritis Knee Pain Treatment, Shares Skyrocket TheStreet.com
03:42PM  Flexion soars on FDA drug approval CNBC Videos
03:25PM  Burlington biotech Flexion eyes expansion after FDA approves pain drug American City Business Journals
03:23PM  Flexion shares surge 18% on news of FDA approval for non-opioid knee pain injection MarketWatch
03:07PM  Flexion's knee pain drug gets FDA nod Reuters
03:00PM  Flexion Therapeutics Announces FDA Approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain GlobeNewswire
09:27AM  Paratek Shares Higher on Microbiology Data -- Biotech Movers TheStreet.com
03:00AM  Flexion Therapeutics Hits 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
Oct-05-17 02:35PM  Big Day on Deck for Flexion Therapeutics Motley Fool
07:16AM  What You Must Know About Flexion Therapeutics Incs (FLXN) Risks Simply Wall St.
Oct-04-17 08:05AM  Outlook for FDA Approval of Zilretta ACCESSWIRE
Oct-03-17 08:14AM  The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO Zacks
03:00AM  Stocks Showing Rising Market Leadership: Flexion Therapeutics Earns 85 RS Rating Investor's Business Daily
Oct-02-17 09:11AM  3 Biotech and Pharma Stocks with Key FDA Catalysts this October Zacks +8.52%
Sep-29-17 03:00AM  Flexion Therapeutics Sees Relative Strength Rating Improve To 75 Investor's Business Daily
Sep-19-17 08:36AM  Implied Volatility Surging for Flexion Therapeutics (FLXN) Stock Options Zacks
Sep-07-17 07:30AM  Flexion Therapeutics to Present Data on Zilretta (FX006) at PAINWeek 2017 GlobeNewswire
Aug-30-17 07:30AM  Flexion Therapeutics to Present at the 2017 Wells Fargo Healthcare Conference GlobeNewswire
Aug-25-17 01:30PM  'Date' These Potential Biotech Winners TheStreet.com
Aug-13-17 07:26AM  Edited Transcript of FLXN earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-17 11:57PM  Flexion Therapeutics reports 2Q loss Associated Press
04:05PM  Flexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
11:10AM  Investor Network: Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 02:06PM  Why Flexion Therapeutics Shares Shot 12.8% Higher in July Motley Fool
Aug-02-17 01:54PM  3 Exciting Biotechs Under $30: Flexion Therapeutics' Response to the Opioid Epidemic Motley Fool
08:15AM  3 Biotech Stocks With Big News Coming Motley Fool
Aug-01-17 07:30AM  Flexion Therapeutics to Report Second-Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
Jul-31-17 10:07AM  3 Hot Healthcare Stocks Under $30 Motley Fool -5.39%
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bodick NeilChief Scientific OfficerMay 11Option Exercise0.1637,7026,130112,307May 11 04:07 PM
Bodick NeilChief Scientific OfficerNov 21Buy24.661,00024,6561,000Nov 22 05:28 PM
Bodick NeilChief Scientific OfficerNov 21Buy24.391,70041,45764,605Nov 22 05:28 PM
Clayman Michael D.President and CEONov 08Buy23.605,000118,00035,395Nov 09 09:13 AM
Deniz YamoChief Medical OfficerSep 05Buy24.201,00024,2009,000Sep 15 05:12 PM
Deniz YamoChief Medical OfficerSep 01Buy24.153,00072,4508,000Sep 15 05:12 PM
Deniz YamoChief Medical OfficerAug 31Buy25.401,37534,9255,000Sep 15 05:12 PM
Stejbach MarkDirectorJun 16Buy17.021,58026,8881,580Jun 20 04:24 PM
COLELLA SAMUEL DDirectorJun 05Buy17.015,00085,0485,000Jun 06 06:49 PM
Clayman Michael D.President and CEOJun 05Buy17.235,00086,15220,146Jun 06 06:47 PM